Revospirone: An Unmarketed Azapirone Veterinary Tranquilizer[edit | edit source]
Revospirone (Bay Vq 7813) is an azapirone derivative that was patented with an indication as a veterinary tranquilizer. Despite its therapeutic potential, the drug was never commercially introduced. Its pharmacodynamic profile is characterized by its activity at the 5-HT1A receptor, with its metabolism leading to an interesting byproduct that imparts additional pharmacological actions.
Revospirone operates through multiple molecular mechanisms, as detailed below:
5-HT1A Receptor Interaction: Revospirone is a selective 5-HT1A receptor partial agonist[1]. This receptor is implicated in a range of functions, including mood regulation and anxiety.
Metabolism and Active Metabolite: Like other azapirones, such as buspirone, revospirone undergoes biotransformation to produce 1-(2-pyrimidinyl)piperazine (1-PP) as an active metabolite[2].
α2-Adrenergic Receptor Interaction: Due to its metabolite 1-PP, revospirone exhibits activity as an α2-adrenergic receptor antagonist[3]. This receptor plays a role in the regulation of neurotransmitter release, adding to the compound's tranquilizing properties.
Revospirone was developed under the aegis of Bay Pharmaceuticals and was patented for veterinary use. However, its journey from patent to market was halted for reasons that remain undisclosed in the public domain. It joins the roster of many promising drugs that, for various reasons, do not reach commercial availability[4].
Azapirones represent a class of drugs known for their anxiolytic properties. Revospirone shares similarities with other compounds in this class:
Buspirone: Likely the most recognized azapirone, buspirone is utilized for the management of generalized anxiety disorder in humans. Both drugs produce the 1-PP metabolite, contributing to their therapeutic effects[5].
Others: Various other azapirones have been studied or marketed for different indications, including gepirone and ipsapirone. The class overall is characterized by its 5-HT1A receptor agonism and the potential α2-adrenergic receptor antagonism due to the 1-PP metabolite.
Though never reaching the shelves, revospirone adds to the knowledge base of veterinary tranquilizers and the broader class of azapirones. Its dual mechanism of action, targeting both the serotonergic and adrenergic systems, underscores the complexity and potential of drug pharmacology in treating various conditions.
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer. Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
